Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 27553377.
- Also identified by PMC identifier 5106608.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.
Medical subject headings
- Antiviral Agents
- Carbamates
- Drug Therapy, Combination
- Hepatitis C, Chronic
- Heterocyclic Compounds, 4 or More Rings
- Opiate Substitution Treatment
- Sofosbuvir